11/06/2015
NESCA delegation (South African Republic) Visited Leningrad NPP
In the beginning of June a team of experts from South-African corporation NESCA (Nuclear Energy Corporation of South Africa) arrived with a working visit at Leningrad NPP (affiliate of JSC Concern Rosenergoatom, Leningrad region). In the course of the visit the guests toured the operating unit of Leningrad NPP engaged in fabrication of various isotope products.
The Russian party was represented at the meeting by SC Rusatom Overseas, JSC Isotope and JSC Concern Rosenergoatom. The purpose of the meeting was to discuss the opportunities and prospects of radioisotope products manufacturing at the capacities of Leningrad NPP.
In his welcome address Mr. Sergey Gubin, Acting Director of the Leningrad NPP, noted that nuclear engineers of the Leningrad NPP have been successfully manufacturing isotope products since 1996. Due to its technological capabilities the Leningrad NPP produces over 15 radioactive isotopes for medical and industrial use. In particular, the successfully arranged production of Cobalt-60 (Co-60) allowed Russia to occupy a significant share of the world market in this segment.
Mrs. Marina Nefedova, Deputy Director General of SC Rusatom Overseas, commented on some results of the meeting: «The meeting held today is important not only for the participants, but also for the entire world medical society. The issues associated with the production of the most consumed medical radioisotope Molybdenum-99 (Мо-99) concern the experts all over the world. ROSATOM production capacities allow to arrange the production of Мо-99 to cover its possible deficit on the global scale. It is important to emphasize that Мо-99 production at the capacities of the Leningrad NPP could be arranged on the basis of Low-Enrichment Uranium (LEU). Our colleagues from the South Africa are one of global market leaders in the sphere of Mo-99 production. They were the first to develope the full-scope LEU-production of this isotope. The application of this technology at the industrial capacities of ROSATOM allows not only to contribute to the development of Russian nuclear industry, but also to make an important step towards ensuring sustainable development of the global nuclear medicine market».
Read original article here.
